Choosing between family members is always a balancing act

Affiliations

¹ Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne.
² Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne. john.seymour@petermac.org.

Editorial

Rory Bennett et al. Haematologica. 2023.

. 2023 Aug 1;108(8):1975-1978.

doi: 10.3324/haematol.2022.282628.

¹ Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne.
² Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne. john.seymour@petermac.org.

No abstract available

Comment on

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.

1. Mauro FR, Starza ID, Messina M, et al. . High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. Haematologica. 2023;108(8):2091-2100. - PMC - PubMed
1. Fischer K, Al-Sawaf O, Bahlo J, et al. . Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236. - PubMed
1. Seymour JF, Kipps TJ, Eichhorst B, et al. . Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120. - PubMed
1. Eichhorst B, Niemann C, Kater AP, et al. . A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the International Intergroup GAIA (CLL13) trial. Blood. 2021;138(Suppl 1):71. - PubMed
1. Eichhorst B, Niemann C, Kater A. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior chemoimmunotherapy in frontline chronic lymphocytic leukaemia (CLL): PFS co-primary endpoint of the randomised phase 3 GAIA/CLL13 trial. Presented at: 2022 EHA Congress Vienna, Austria. EHA Library. Eichhorst B. 06/12/2022; 366209; LB2365.